Therapy Areas: Autoimmune
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human U...
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Hu...
Japan approves Wayrilz for immune thrombocytopenia treatment
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that Japan's Ministry of Health, Labour and Welfare has granted marketing and manufactu...
Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026
16 June 2026 - Minghui Pharmaceutical, a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, announced on Monday the presenta...
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
10 June 2026 - US healthcare company Organon (NYSE:OGN) on Wednesday announced US Food and Drug Administration (FDA) approval of a supplemental Biologics License Application for TOFIDENCE (tocilizumab...
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
10 June 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, announced on Tuesday that its partner, Formation Bio, ...